Cancer incidence varies among different induction agents and different population. We aim to compare the incidence of cancer post kidney transplantation among different induction agents at our center. Material and Methods: We analyzed prospectively collected data of 2981 renal transplant performed at King Faisal Specialist Hospital and Research Centre KSA between 1981 and 2016 with a median follow-up period of 153 months. Statistical analysis was carried out using SPSS 21. Results: Overall there was 4.2% (n=125) incidence of post renal transplant malignancies recorded in our patients with equal distribution among pediatric and adult recipients [RR 1.0106; 95% CI 0.5927 to 1.7231; P = 0.96921. The median time from transplant to malignancy was 53 months. Fresenius ATG was associated with higher incidence of cancer [ RR 1.63; 95% CI (1.06-2.52); p =0.026]. Non-cutaneous carcinomas (n=42) were the commonest malignancy followed by PTLD (n=33). The incidence of PTLD was higher in pediatric group as compared to adults [RR 3.4667; 95% CI 1.2050 to 2.4504; P <0.0001]. Likewise the incidence of non-cutaneous carcinoma was higher in adult as compared with pediatric population [RR 2.343; 95% CI 1.2204 to 2.042; P <0.0001]. The overall mortality was 7.45% during the median follow-up period of 153 months. Patients with malignancy had higher mortality rate of 29.24% as compared to 6.64% in non-malignancy group [P= <0.0001]. Death with functioning graft (DWFG) was significantly more in malignant group [P=<0.0001]. Conclusion: The overall rate of malignancy remains low (4.2%) when compared to the international rat. Fresenius ATG was associated with highest incidence of cancer compared to other agents. Mortality was significantly higher with cancer development and PTLD was common among pediatric patients particularly EBV negative.

CITATION INFORMATION: AlEid H., Raza S., Ali T., Alahmadi I., Aleid S., Broering D. Cancer Incidence after Kidney Transplantation in Saudi Arabia, Comparing Different Induction Agents Am J Transplant. 2017;17 (suppl 3).

« Back to 2018 American Transplant Congress